cholestane-3,7,12,26-tetrol: precursor of cholic acid biosyn in man; RN given refers to (3alpha,5beta,7alpha,12alpha)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 193321 |
| CHEBI ID | 17278 |
| SCHEMBL ID | 4431740 |
| MeSH ID | M0073838 |
| Synonym |
|---|
| cholestane-3,7,12,26-tetrol |
| CHEBI:17278 |
| (3alpha,5beta,7alpha,12alpha)-cholestane-3,7,12,26-tetrol |
| cholestane-3,7,12,27-tetrol |
| 5beta-cholestane 3alpha,7alpha,12alpha,27-tetrol |
| cholestane-3,7,12,26(27)-tetrol |
| 862-53-3 |
| 5beta-cholestane-3alpha,7alpha,12alpha,26-tetrol |
| 3alpha,7alpha,12alpha,26-tetrahydroxy-5beta-cholestane |
| 5beta-cholestane-3alpha,7alpha,12alpha,26-tetraol |
| C05446 |
| LMST04030014 |
| 5-cttl |
| SCHEMBL4431740 |
| 5b-cholestane-3a,7a,12a,27-tetrol |
| 5beta-cholestane-3alpha,7alpha,12alpha,27-tetrol |
| 27-deoxy-5beta-cyprinol |
| 5-b-cholestane-3a-7-tetraol |
| 5b-cholestane-3a,7a,12a,26-tetrol |
| 27-deoxy-5b-cyprinol |
| 5beta-cholestane-3alpha,7alpha,12alpha,27alpha-tetrol |
| 5-beta-cholestane-3a-7-tetraol |
| 3a,7a,12a,26-tetrahydroxy-5b-cholestane |
| 5beta-cholestane-3alpha,7alpha,12alpha,27-tetraol |
| (25r)-5-beta-cholestane-3-alpha,7-alpha,12-alpha,26-tetraol |
| 5-beta-cholestane-3-alpha-7-alpha-12-alpha-26-tetraol |
| DTXSID60862444 |
| Q27102298 |
| (3r,5s,7r,9s,10s,12s,13r,14s,17r)-17-((2r)-7-hydroxy-6-methylheptan-2-yl)-10,13-dimethylhexadecahydro-1h-cyclopenta[a]phenanthrene-3,7,12-triol |
| Role | Description |
|---|---|
| human metabolite | Any mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens). |
| mouse metabolite | Any mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus). |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| 3alpha-hydroxy steroid | A 3-hydroxy steroid in which the 3-hydroxy substituent is in the alpha-position. |
| 7alpha-hydroxy steroid | A 7-hydroxy steroid in which the hydroxy group at position 7 has an alpha-configuration. |
| 12alpha-hydroxy steroid | |
| 26-hydroxy steroid | Any hydroxy steroid in which a hydroxy group is located at position 26. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (42.86) | 18.7374 |
| 1990's | 4 (57.14) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.43) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||